InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

Current share price for MSB : $1.790 0.02 (1.13%)+

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,329 Ceasing to be a substantial holder 27 Nov 2025 6:32PM $2.690 $1.790 fallen by 33.46%
$2,329 Results of Meeting 25 Nov 2025 2:32PM $2.365 $1.790 fallen by 24.31%
$2,329 Ryoncil Revenue Growth Highlighted in AGM Trading Update 25 Nov 2025 10:00AM $2.330 $1.790 fallen by 23.18%
$2,329 CEO Presentation to 2025 Annual General Meeting 25 Nov 2025 9:52AM $2.330 $1.790 fallen by 23.18%
$2,329 Mesoblast Chair Message to 2025 AGM 25 Nov 2025 9:49AM $2.330 $1.790 fallen by 23.18%
$2,329 Mesoblast & BMT CTN to Initiate Adult aGvHD Trial of RYONCIL 21 Nov 2025 9:54AM $2.300 $1.790 fallen by 22.17%
$2,329 Appointment of Chief Financial Officer 17 Nov 2025 9:53AM $2.220 $1.790 fallen by 19.37%
$2,329 FDA meeting on Rexlemestrocel-L, CLBP and Opioid Cessation 5 Nov 2025 9:58AM $2.410 $1.790 fallen by 25.73%
$2,329 Becoming a substantial holder 29 Oct 2025 4:59PM $2.510 $1.790 fallen by 28.69%
$2,329 Change of Director's Interest Notice 28 Oct 2025 1:02PM $2.555 $1.790 fallen by 29.94%
$2,329 Notification regarding unquoted securities - MSB 28 Oct 2025 12:50PM $2.555 $1.790 fallen by 29.94%
$2,329 Annual Report to Shareholders 27 Oct 2025 9:38AM $2.570 $1.790 fallen by 30.35%
$2,329 Notice of Annual General Meeting and Proxy Form 27 Oct 2025 9:23AM $2.570 $1.790 fallen by 30.35%
$2,329 Appendix 4G and Corporate Governance Statement 27 Oct 2025 9:16AM $2.570 $1.790 fallen by 30.35%
$2,329 Ceasing to be a substantial holder 23 Oct 2025 6:33PM $2.600 $1.790 fallen by 31.15%
$2,329 Becoming a substantial holder 22 Oct 2025 5:20PM $2.700 $1.790 fallen by 33.70%
$2,329 Quarterly Activities/Appendix 4C Cash Flow Report 20 Oct 2025 9:47AM $2.620 $1.790 fallen by 31.68%
$2,329 Ceasing to be a substantial holder 15 Oct 2025 8:26AM $2.760 $1.790 fallen by 35.14%
$2,329 Notification of cessation of securities - MSB 14 Oct 2025 6:18PM $2.760 $1.790 fallen by 35.14%
$2,329 Notification regarding unquoted securities - MSB 14 Oct 2025 6:17PM $2.760 $1.790 fallen by 35.14%
$2,329 Application for quotation of securities - MSB 14 Oct 2025 6:14PM $2.760 $1.790 fallen by 35.14%
$2,329 Appendix 3Y for Eric Rose 14 Oct 2025 6:07PM $2.760 $1.790 fallen by 35.14%
$2,329 Becoming a substantial holder 14 Oct 2025 8:21AM $2.820 $1.790 fallen by 36.52%
$2,329 Ryoncil Revenues Increase 66% in Second Quarter Post Launch 7 Oct 2025 9:44AM $2.590 $1.790 fallen by 30.89%
$2,329 Ryoncil Receives CMS (Medicaid) J-Code for Reimbursement 3 Oct 2025 10:03AM $2.630 $1.790 fallen by 31.94%

101 - 125 of 1197 results

Page 5 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.